SERVICES

Tag Archives | Rexin-G

Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

Continue Reading

Part of the Neotrope® News Network, USA. Neotrope.net